In addition, HDACis (romidepsin and chidamide) have been confirmed their effects in restoring CEBPA expression and reversing cellular dedifferentiation in vitro in EBV+ NPC [55]. This evidence concerns the gene CEBPA and nasopharyngeal carcinoma.